🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Alan P Skarbnik

Cancer Institute (WIA)

ORCID: 0000-0002-1276-7546

Also affiliated with Novant Health

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial”.

Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial

The Lancet Haematology(2022)10.1016/s2352-3026(22)00318-0

N/A

1.4DataRank · unranked

41 citations

Lu Chen, Yago Nieto, Leona Holmberg, Patrick B. Johnston, Matthew Mei +20 more

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Blood(2025)10.1182/blood.2024024476

N/A

0.710DataRank · unranked

42 citations

Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, Krish Patel, Ian W. Flinn +22 more

An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL

Blood Advances(2024)10.1182/bloodadvances.2023012142

N/A

0.569DataRank · unranked

18 citations

John N. Allan, Dan James, Helen Bridge, Miguel Miranda, Alan SM Yong +6 more

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Blood(2021)10.1182/blood.2021011841

N/A

0DataRank · unranked

70 citations

Toby A. Eyre, Meghan C. Thompson, Nicole Lamanna, Alexander Coltoff, Matthew S. Davids +47 more

Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study

Blood Advances(2024)10.1182/bloodadvances.2023011569

N/A

0DataRank · unranked

11 citations

Jenna Voutsinas, Bita Fakhri, Sirin Khajavian, Stephen E. Spurgeon, Deborah M. Stephens +30 more

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

Blood(2020)10.1182/blood.2020006288

N/A

0DataRank · unranked

340 citations

Jorge J. Castillo, Alan P Skarbnik, Jacob D. Soumerai, Irene M. Ghobrial, Maria Luisa Guerrera +3 more

Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL

Blood Cancer Journal(2025)10.1038/s41408-025-01236-6

N/A

0DataRank · unranked

12 citations

Ying Huang, Sarah Miller, John N. Allan, Seema A. Bhat, David A. Bond +40 more

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3815

N/A

0DataRank · unranked

116 citations

Lindsey E. Roeker, Ryan Jacobs, Brian T. Hill, Nicole Lamanna, Danielle M. Brander +49 more

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

Blood Advances(2020)10.1182/bloodadvances.2020001956

N/A

0DataRank · unranked

86 citations

Peter Dreger, Jennifer R. Brown, Oscar Lahoud, Toby A. Eyre, Danielle M. Brander +20 more